Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 1999

View Archived Issues

Nexell awarded U.S. patent for neutropenia therapy

Avanir signs letter of intent with IriSys for ALS drug

NIH to initiate clinical trials of Novavax's Novasome spermicide

Ligand seeks approval for Panretin Gel in Europe

Alkermes acquires Advanced Inhalation Research

Orion seeks approval for injectable levosimendan in the U.S.

Cholesterol-lowering action of troglitazone points to a potential new target for hypolipidemic drugs

Fenamate-derived antiinflammatory agents in development at Abbott

G120K-PEG: a specific renal GHR antagonist for the treatment of diabetic kidney disease

Cathepsin L inhibitor isolated by Yamanouchi

New antibacterial series produced by Streptomyces discovered by Kyowa Hakko

Otsuka's new anti-H. pylori agents for GI disorders

Effects of NS-7 on Ca2+ channel subtypes and NOS

Cardioprotective agent JTV-519 evaluated for neuronal effects

Effects of NS-105 on cAMP production involve different mGluR groups

Dexemel drug delivery vehicle approved in the U.K.

Boston team reports further successes with naked DNA gene transfer as therapy for angina

ECyd evaluated for mechanism of action, potential clinical activity

Anti-CMV MAb slows disease progression in AIDS patients

Trovan I.V. potentially incompatible with normal saline and lactated Ringer's solutions

Lexigen's HIV fusion inhibitor is safe and effective in phase II trial

Combination of TZT-1027 + ara-C provides synergistic antitumor activity

Inadvertent overdoses of Cerebyx due to labeling confusion lead to death

Inflazyme and HMR to collaborate on allergy, asthma and respiratory disease therapies

Biota's inhaled influenza drug recommended for approval in Australia

NIAID opens phase I trial of vCP205 in Uganda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...